ALOFISEL Drug Insight

“ALOFISEL Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about ALOFISEL for Crohn’s Disease in the 7MM. A detailed picture of the ALOFISEL for Crohn’s Disease in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the ALOFISEL for Crohn’s Disease. The ALOFISEL Market report provides insight about ALOFISEL mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ALOFISEL market forecast, analysis for Crohn’s Disease in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Crohn’s Disease.

ALOFISEL Drugs Market Report Summary

ALOFISEL (Darvadstrocel) is a suspension of allogeneic (or donor-derived) Expanded Adipose-Derived Stem cCells (eASC) for the treatment of complex perianal fistulas in adult patients with non-active or mildly active luminal Crohn’s Disease. ALOFISEL was granted orphan drug designation by the Japanese Ministry of Health, Labor, and Welfare in March 2019. In Japan, ALOFISEL is indicated for the treatment of complex perianal fistulas in patients with non-active or mildly active luminal Crohn’s Disease. This product is indicated for the treatment of patients who have shown an inadequate response to at least one existing medicinal treatment.

By exhibiting immunomodulatory and local anti-inflammatory effects at the site of inflammation, ALOFISEL offers a new treatment option with the potential of cell-mediated closure for complex perianal fistulas in patients with non-active or mildly active luminal Crohn’s disease who have shown an inadequate response to at least one existing medicinal treatment. It is a made-to-order therapy that must be administered within 72 hours of manufacture.

ALOFISEL Mechanism of action

Darvadstrocel contains expanded adipose stem cells (eASC), which exhibit immunomodulatory and anti-inflammatory effects at inflammation sites. Anal fistulas treatment market typically present as fissures penetrating the intestinal lumen and perianal skin surface and are characterized by local inflammation that is exacerbated by bacterial infections and fecal contamination. In the inflamed area, activated lymphocytes infiltrate and inflammatory cytokines are released locally.

Inflammatory cytokines, particularly IFN-, are released by activated immune cells (i.e., lymphocytes), and they activate eASC. Once activated, eASC impairs the proliferation of activated lymphocytes and reduces the release of proinflammatory cytokines. This immunoregulatory activity reduces inflammation, allowing the tissues around the fistula tract to heal.

ALOFISEL Drugs Market Report Scope

The report provides insights into:

•  A comprehensive product overview including the ALOFISEL description, ALOFISEL mechanism of action, dosage and administration, research and development activities in Crohn’s Disease.
•  Elaborated details on ALOFISEL regulatory milestones and other development activities have been provided in this report.
•  The report also highlights the ALOFISEL research and development activity in Crohn’s Disease in detail across the United States, Europe and Japan.
•  The report also covers the patents information with expiry timeline around ALOFISEL.
•  The report contains forecasted sales of ALOFISEL for Crohn’s Disease till 2032.
•  Comprehensive coverage of the late-stage emerging therapies for Crohn’s Disease.
•  The report also features the SWOT analysis with analyst views for ALOFISEL in Crohn’s Disease.

ALOFISEL Methodology

The ALOFISEL drugs market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ALOFISEL Market  Analytical Perspective by DelveInsight

• In-depth ALOFISEL Market Assessment

This ALOFISEL drugs market report provides a detailed market assessment of ALOFISEL in Crohn’s Disease in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

• ALOFISEL Clinical Assessment

The ALOFISEL drugs market report provides the clinical trials information of ALOFISEL in Crohn’s Disease covering trial interventions, trial conditions, trial status, start and completion dates.

ALOFISEL Market Forecast Report Highlights 

•  In the coming years, the ALOFISEL market scenario for Crohn’s Disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
•  The ALOFISEL Companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ALOFISEL dominance.
•  Other emerging products for Crohn’s Disease are expected to give tough market competition to ALOFISEL and launch of late-stage emerging therapies in the near future will significantly impact the market.
•  A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ALOFISEL in Crohn’s Disease.
•  Our in-depth analysis of the forecasted sales data of ALOFISEL from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ALOFISEL in Crohn’s Disease.  

Key Questions

•  What is the product type, route of administration and ALOFISEL mechanism of action?
•  What is the clinical trial status of the study related to ALOFISEL in Crohn’s Disease and study completion date?
•  What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ALOFISEL development?
•  What are the key designations that have been granted to ALOFISEL for Crohn’s Disease?
•  What is the forecasted market scenario of ALOFISEL for Crohn’s Disease?
•  What are the forecasted sales of ALOFISEL in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
•  What are the other emerging products available in Crohn’s Disease and how are they giving competition to ALOFISEL for Crohn’s Disease?
•  Which are the late-stage emerging therapies under development for the Crohn’s Disease treatment?

Stay Updated with us for Recent Articles @ Latest DelveInsight Blogs